SeaStar Medical
About: SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
Employees: 19
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
33% more funds holding
Funds holding: 15 [Q3] → 20 (+5) [Q4]
0.79% more ownership
Funds ownership: 3.26% [Q3] → 4.05% (+0.79%) [Q4]
40% less capital invested
Capital invested by funds: $584K [Q3] → $352K (-$232K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for ICU.
Financial journalist opinion
Neutral
GlobeNewsWire
20 hours ago
SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time
DENVER, April 30, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, CEO of SeaStar Medical, will be a featured guest today, Wednesday, April 30th, at approximately 10:50 am Eastern Time on the Benzinga All Access Show.
Neutral
GlobeNewsWire
3 weeks ago
FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery
DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Food and Drug Administration (FDA) has granted SeaStar Medical two new Breakthrough Device Designations for its Selective Cytopheretic Device (SCD) therapy. The two new Breakthrough Device Designations are indicated for the treatment of systemic inflammatory response in 1) adult patients undergoing cardiac surgery and 2) pediatric patients undergoing cardiac surgery towards prevention of post-operative adverse complications and outcomes. Approximately 15 percent of the estimated 300,000 adults that undergo cardiac surgery each year are considered high risk and, we believe, could benefit most from the SCD therapy to prevent post-surgical complications. Of the 40,000 pediatric patients that undergo congenital heart surgery each year, we believe that approximately one third might benefit from SCD therapy.
Neutral
GlobeNewsWire
1 month ago
SeaStar Medical Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
DENVER, March 27, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2024, and provided business updates on key initiatives. “Our significant accomplishment in 2024 position us well for a transformational year in 2025,” said Eric Schlorff, SeaStar Medical CEO.
Neutral
GlobeNewsWire
1 month ago
SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
DENVER, March 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2024 financial results after market close on Thursday, March 27, 2025, and host a webcast and conference call to discuss its financial results and business progress.
Neutral
PRNewsWire
1 month ago
NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award
Company recognized for treatment recently approved in the U.S. for pediatric acute kidney injury (AKI) due to sepsis. NEW YORK , March 18, 2025 /PRNewswire/ -- SeaStar Medical (Nasdaq: ICU) has been selected to receive the 2025 Corporate Innovator Award from the National Kidney Foundation (NKF) at the 2025 Spring Clinical Meetings in Boston.
Neutral
GlobeNewsWire
2 months ago
SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market
DENVER, Feb. 03, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rule, with a single institutional investor for the issuance and sale of an aggregate of 3,529,412 shares of its common stock (or pre-funded warrants in lieu thereof). In a concurrent private placement, the Company issued and sold to the investor warrants to purchase up to an aggregate of 3,529,412 shares common stock.
Neutral
GlobeNewsWire
3 months ago
SeaStar Medical Activates 15th Site for its Adult Acute Kidney Injury Pivotal Trial
DENVER, Jan. 22, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Mayo Clinic is now cleared to enroll subjects in the company's NEUTRALIZE-AKI pivotal trial, increasing the number of activated sites to 15.
Neutral
GlobeNewsWire
3 months ago
FDA Approves Feasibility Study with SeaStar Medical's Selective Cytopheretic Device in Adults with Cardiorenal Syndrome
Study to be conducted under $3.6 million NIH grant DENVER, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to evaluate the safety and initial efficacy of SeaStar Medical's Selective Cytopheretic Device (SCD-ADULT) in reducing inflammation in adult patients with acute heart failure with worsening renal function due to cardiorenal syndrome or severe right ventricular failure awaiting a left ventricular assist device (LVAD) implantation. This feasibility study is expected to enroll 20 patients at up to five clinical sites and will be funded by a previously announced $ 3.6 million National Institutes of Health (NIH) grant awarded to Innovative BioTherapies (IBT), which is led by SCD inventor H.
Neutral
GlobeNewsWire
3 months ago
SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer
DENVER, Jan. 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces the shipment of its QUELIMMUNE™ device to a prominent academic medical center, representing SeaStar Medical's fourth commercial customer. QUELIMMUNE is the company's Selective Cytopheretic Device (SCD) for treating critically ill children in the intensive care unit (ICU) with acute kidney injury (AKI) and sepsis.
Neutral
GlobeNewsWire
4 months ago
SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial
DENVER, Dec. 23, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that a 14th site is now activated and able to enroll subjects in the NEUTRALIZE-AKI pivotal trial. The NEUTRALIZE-AKI trial is evaluating the safety and efficacy of the Company's proprietary therapeutic Selective Cytopheretic Device (SCD) in patients with acute kidney injury (AKI) in the intensive care unit (ICU) receiving continuous renal replacement therapy (CRRT).
Charts implemented using Lightweight Charts™